Effects of LDL-C-lowering drugs on PCSK9
Author Information
Author(s): Konrad Robert J, Troutt Jason S, Cao Guoqing
Primary Institution: Lilly Research Laboratories, Eli Lilly and Company
Hypothesis
Statins and other lipid-lowering medications increase serum PCSK9 levels, which may limit their effectiveness in lowering LDL-C.
Conclusion
Commonly prescribed lipid-lowering medications increase serum PCSK9 levels, which may explain their limited effectiveness in lowering LDL-C.
Supporting Evidence
- Statins have been shown to increase PCSK9 levels in humans.
- Fenofibrate significantly increased PCSK9 levels in a study.
- Ezetimibe also increases PCSK9 levels when added to statin therapy.
Takeaway
Some medicines that lower bad cholesterol can actually raise a protein called PCSK9, which makes them less effective at lowering cholesterol.
Methodology
The study reviewed existing literature on the effects of statins, ezetimibe, and fibrates on PCSK9 levels.
Limitations
The study primarily reviews existing literature and may not include new experimental data.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website